Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 15:27:48 - browse：3657

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： PBM reform efforts get punted in Congress

WSS

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Shingles, which affected Dianne Feinstein, is on the rise

After a drawn out lobbying fight, ARPA

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

STAT readers on older presidents, polypills, Medicare, and more

explore

Wikipedia

focus

In Memoriam: Notable people who died in 2023

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Medical records are filled with copy

Ionis has late

BioMarin wins approval for gene therapy to treat hemophilia A

PBM reform efforts get punted in Congress

Continuity nursing helped my family in our darkest PICU moments

FDA advisers vote against ALS treatment from BrainStorm

Walensky prepares to leave CDC — and Congress — behind

With competition flaring, obesity drug hits goal in liver disease study

focus

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

After a drawn out lobbying fight, ARPA

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

hotspot

explore

explore

hotspot